Moderna stock fell on Thursday, September 3, after Rothschild & Co. Redburn downgraded MRNA from Neutral to Sell, arguing that the spectacular rally following Moderna and Merck’s Phase 3 melanoma breakthrough has pushed the valuation far beyond what current clinical evidence can justify. Analyst Simon Baker actually more than doubled his price target from $40 to $81, but that target still sits roughly 44% below where Moderna traded before Thursday’s decline, turning the downgrade into one of the strongest bearish calls on Wall Street after the stock surged 156% in August.
The downgrade does not challenge the importance of Moderna’s cancer-vaccine breakthrough itself. Rothschild described the Phase 3 result as a major success. Instead, the debate has shifted dramatically from whether Moderna’s mRNA technology can work in cancer to whether investors have already priced in successful expansion across multiple additional tumor types for which convincing late-stage evidence does not yet exist.
Moderna Stock Gets a Rare Sell Rating
Rothschild & Co. Redburn analyst Simon Baker cut Moderna stock to Sell from Neutral on Thursday while simultaneously lifting his price target to $81 from $40. That unusual combination tells investors almost everything they need to know about the debate surrounding MRNA right now: Rothschild believes the fundamental value of Moderna’s pipeline has improved significantly, but the share price has risen much faster than the firm’s estimate of that value.
Moderna had closed Wednesday at $150.81 before opening lower Thursday, and the shares were trading around $144 during the U.S. session. An $81 target would therefore imply substantial downside even after Thursday’s decline. Rothschild’s central concern is that investors appear to be valuing intismeran autogene as though the therapy will ultimately become broadly successful across numerous forms of cancer, despite the fact that the strongest clinical evidence currently comes from melanoma.
That is a very different argument from saying Moderna’s science failed. In fact, Rothschild explicitly called the Phase 3 melanoma result a “great result.” The issue is what investors should reasonably pay today for future oncology indications that remain unproven. That distinction is critical because Moderna is no longer trading like a distressed post-COVID vaccine company. After its extraordinary August rally, investors are increasingly valuing it as a potentially major oncology platform.
Related articles
The Cancer-Vaccine Breakthrough Really Was Historic
Any bearish Moderna argument has to begin by acknowledging why the stock exploded in the first place. On August 19, Moderna and Merck announced that intismeran autogene combined with Keytruda met both the primary and key secondary endpoints in the Phase 3 INTerpath-001 trial involving 1,137 patients with surgically removed high-risk melanoma. The combination significantly improved recurrence-free survival and reduced the risk of the cancer spreading to distant parts of the body compared with Keytruda alone.
The result represented the first successful large late-stage trial of a personalized mRNA cancer vaccine, giving Moderna the strongest evidence yet that the technology behind its COVID-19 vaccine can become a meaningful therapeutic platform beyond infectious disease. Moderna’s personalized treatment is designed around mutations found in each patient’s tumor, effectively teaching the immune system to identify and attack cancer cells carrying those mutations.
Investors reacted accordingly. Moderna shares surged as much as 177% in a single session on August 19, closing at $174.38 and adding tens of billions of dollars in market value. The stock ultimately gained approximately 156% during August, making Moderna the strongest performer in the S&P 500 for the month.
For a company that had spent years struggling with collapsing COVID-vaccine demand and investor skepticism about its pipeline, the clinical result fundamentally changed the narrative. Moderna suddenly had evidence that its mRNA platform could produce something investors had hoped for since the pandemic: a potentially blockbuster product in oncology.
The Valuation Problem Is Now Much Bigger Than Melanoma
The question is how much that success is actually worth.
Reuters Breakingviews argued immediately after the Phase 3 announcement that the approximately $30 billion increase in Moderna’s equity value implied investors were assuming success across multiple cancers, not simply melanoma. The concern was straightforward: even a commercially successful melanoma vaccine alone may not justify the enormous market-cap increase that occurred in a single day.
Rothschild is now making essentially the same argument in more aggressive form. According to the firm, Moderna’s current valuation appears to assume something close to widespread adoption of intismeran across numerous tumor types despite relatively limited clinical evidence outside melanoma.
That matters because different cancers behave very differently. Melanoma generally contains a high number of mutations, giving a personalized vaccine more potential targets for the immune system. Other tumors may be much more difficult. Success in melanoma therefore does not automatically prove that exactly the same approach will produce equivalent results in lung, kidney, bladder or other cancers.
If additional late-stage studies succeed, Moderna’s current valuation could eventually look much more reasonable. If they do not, investors may discover that they paid in advance for revenue streams that never materialize.
BioNTech Just Showed Why Cancer Vaccines Remain Risky
A development from Moderna rival BioNTech reinforces that uncertainty.
On August 28, BioNTech and Genentech halted a Phase 2 study of their personalized mRNA cancer vaccine autogene cevumeran in colorectal cancer after an independent monitoring committee concluded that the study was unlikely to show an overall-survival benefit. The committee also observed a numerical imbalance in survival between the treatment groups, and BioNTech shares fell around 7.5% following the announcement.
The failure does not invalidate Moderna’s melanoma results because the treatments, trial designs and cancers are different. But it illustrates why extrapolating one successful cancer-vaccine trial across the entire oncology market can be dangerous. Researchers have long found certain “cold” tumors more difficult for immunotherapies to attack than highly mutated cancers such as melanoma.
For Moderna shareholders, that means the next phase of the investment story becomes heavily dependent on additional data. The stock’s enormous rally effectively moved future cancer indications from optional upside toward something the market increasingly expects to succeed.
That is precisely what Rothschild believes has gone too far.
Wall Street Is Deeply Divided on Moderna
The downgrade also highlights an unusually wide disagreement among analysts.
Rothschild is now one of the relatively few firms with an outright Sell rating, while many analysts remain at Hold or Neutral. Barron’s reported that roughly two-thirds of the 24 analysts covering Moderna currently sit in the middle rather than recommending investors aggressively buy or sell the shares. J.P. Morgan is another firm that has expressed caution, emphasizing that further value depends heavily on proving intismeran can work in additional tumor types.
Other firms became substantially more optimistic after the melanoma data. RBC raised its price target from $45 to $130 while maintaining a Sector Perform rating, and Bank of America upgraded Moderna while increasing its target to $170. Those targets illustrate just how dramatically analysts have had to rethink the company after the Phase 3 success.
The important point is that even analysts who remain cautious generally acknowledge Moderna is worth significantly more than they believed before August 19. Rothschild’s own target moving from $40 to $81 demonstrates that clearly. The disagreement is no longer about whether the breakthrough creates value. It is about how much value investors should recognize today before additional trials confirm broader commercial potential.
Moderna Is Still a Loss-Making Company
The stock’s fundamental profile also remains important.
Moderna is still losing money as its post-pandemic respiratory-vaccine business struggles to replace the extraordinary COVID revenues generated earlier in the decade. Market data cited Thursday put the company’s trailing earnings per share around negative $8, leaving MRNA without the conventional earnings valuation framework investors might use for a profitable pharmaceutical company.
That makes pipeline assumptions enormously important. For a mature profitable company, investors can value existing earnings and add some premium for future products. Moderna’s valuation is far more dependent on what its clinical pipeline could eventually become.
That can create extreme volatility in both directions. A positive Phase 3 trial can suddenly add tens of billions of dollars to expected future value. A failed study, regulatory setback or weaker-than-expected commercial launch can remove that value just as quickly.
The stock’s August performance demonstrated the upside version of that dynamic. Thursday’s downgrade is a reminder that the reverse scenario still exists.
Is Moderna Stock Overvalued After the Rally?
The answer depends almost entirely on how broadly intismeran eventually works.
If the vaccine becomes an important melanoma therapy but struggles in additional cancers, Rothschild’s concern could prove justified. Moderna’s market capitalization has already expanded dramatically, and melanoma alone may not generate enough economics for Moderna to support the valuation investors assigned after the August surge, particularly because Merck shares the economics of the program.
If intismeran succeeds across multiple large cancer indications, however, the opportunity changes completely. Personalized cancer vaccines could become one of the most significant new treatment categories in oncology, and Moderna would possess both a validated mRNA platform and years of manufacturing experience that could be difficult for competitors to replicate quickly.
The Phase 3 melanoma result also gives Moderna something it did not have a month ago: genuine clinical validation at the highest stage of drug development. That matters even beyond intismeran because investors can now assign more credibility to the company’s broader mRNA pipeline.
The problem is that the stock market may already be assigning a lot of that credibility.
Moderna Stock Outlook: The Next Trial Matters More Than the Next Analyst
Thursday’s Rothschild downgrade is significant because it directly challenges the valuation investors placed on Moderna after the cancer-vaccine breakthrough. But it does not alter the underlying Phase 3 result, and it does not change the possibility that intismeran eventually becomes a major commercial product.
What it changes is the debate.
Before August 19, investors asked whether Moderna could prove mRNA works beyond COVID vaccines. The melanoma trial provided a powerful answer.
Now investors must ask whether success in melanoma can be repeated across enough cancers to justify a company valued at tens of billions of dollars more than it was only weeks ago.
That question will not ultimately be answered by Rothschild, Bank of America or any other analyst. It will be answered by clinical data.
Until then, Moderna stock is caught between one historic success and a valuation that increasingly assumes several more are coming.
Disclaimer
This article is for informational and educational purposes only and does not constitute financial, investment, tax or legal advice. Nothing published by StockMinded should be considered a recommendation to buy, sell or hold Moderna stock or any other financial instrument.
Biotechnology stocks can experience extreme volatility around clinical-trial results, regulatory decisions and analyst actions. Investors should conduct their own research and consider their financial situation, investment objectives and risk tolerance before making investment decisions.
